首页> 美国卫生研究院文献>Future Medicinal Chemistry >Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies
【2h】

Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies

机译:分子伴侣和tau质量控制的调节:tauopathies中药物发现的策略

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Tau is a microtubule-associated protein that accumulates in at least 15 different neurodegenerative disorders, which are collectively referred to as tauopathies. In these diseases, tau is often hyperphosphorylated and found in aggregates, including paired helical filaments, neurofibrillary tangles and other abnormal oligomers. Tau aggregates are associated with neuron loss and cognitive decline, which suggests that this protein can somehow evade normal quality control allowing it to aberrantly accumulate and become proteotoxic. Consistent with this idea, recent studies have shown that molecular chaperones, such as heat shock protein 70 and heat shock protein 90, counteract tau accumulation and neurodegeneration in disease models. These molecular chaperones are major components of the protein quality control systems and they are specifically involved in the decision to retain or degrade many proteins, including tau and its modified variants. Thus, one potential way to treat tauopathies might be to either accelerate interactions of abnormal tau with these quality control factors or tip the balance of triage towards tau degradation. In this review, we summarize recent findings and suggest models for therapeutic intervention.
机译:Tau是一种与微管相关的蛋白质,可在至少15种不同的神经退行性疾病中累积,这些疾病统称为tauopathies。在这些疾病中,tau通常被过度磷酸化,并存在于聚集体中,包括成对的螺旋状细丝,神经原纤维缠结和其他异常的低聚物。 Tau聚集体与神经元丧失和认知能力下降有关,这表明该蛋白可以以某种方式逃避正常的质量控制,使其异常积累并成为蛋白毒性物质。与此想法相一致,最近的研究表明,分子伴侣蛋白,例如热休克蛋白70和热休克蛋白90,可抵消tau积累和疾病模型中的神经变性。这些分子伴侣是蛋白质质量控​​制系统的主要组成部分,它们特别参与保留或降解许多蛋白质(包括tau及其修饰的变体)的决定。因此,治疗tauopathies的一种潜在方法可能是要么加速异常tau与这些质量控制因素的相互作用,要么将分类的平衡推向tau降解。在这篇综述中,我们总结了最近的发现并提出了治疗干预的模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号